Atherosclerosis Research

Atherosclerosis is a disease of the arterial system that is characterized by the accumulation of fatty deposits within arterial walls, known as 'atherosclerotic plaques'.

Atherosclerosis Research Products Targets

Products for Atherosclerosis Research - Page 8

Cat.No. Product Name Information/Activity
BCC5895 Lyn peptide inhibitor 222018-18-0
BCC5813 Ro 26-4550 trifluoroacetate 1217448-66-2
BCC2368 Sivelestat sodium salt Sivelestat sodium(ONO5046; LY544349; EI546) is a competitive inhibitor of human neutrophil elastase(IC50 = 44 nM; Ki=200 nM); also inhibited leukocyte elastase obtained from rabbit, rat, hamster and mouse.
BCN5524 Betulinic acid Betulinic acid is a natural pentacyclic triterpenoid, acts as a eukaryotic topoisomerase I inhibitor, with an IC50 of 5 μM, and possesses anti-HIV, anti-malarial, anti-inflammatory and anti-tumor properties. Betulinic acid acts as a new activator of NF-kB.
BCC6201 GPBAR-A GPBA receptor (TGR5) agonist
BCN5616 Oleanolic acid Oleanolic acid (Caryophyllin) is a natural compound from plants with anti-tumor activities.
BCC1659 IRAK-1-4 Inhibitor I IRAK-1-4 Inhibitor I is an inhibitor of interleukin-1 receptor-associated kinase 1/4 (IRAK 1/4) with IC50s of 0.2 μM and 0.3 μM, respectively.
BCC2319 Atorvastatin Calcium Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
BCC2317 Fluvastatin Sodium Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin sodium protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.
BCN1060 Lovastatin Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.